Sign in Subscribe
Chairpersons

Resonetics Appoints Kevin Kelly as President and CEO, Tom Burns to Retire

Strategic Insights

— 1 min read

As Resonetics embarks on a new chapter in its history, the medical contract design and manufacturing organization announced the appointment of Kevin Kelly as its new President and CEO, effective May 30, 2023. Tom Burns, the current President and CEO, is retiring and will become Executive Chairman of the Board. Kelly brings a wealth of experience in the medical device industry, having held leadership positions with prominent companies such as Becton Dickinson, C.R. Bard, and Medtronic. His appointment is seen as a significant milestone for Resonetics, which is poised for future growth following the pending acquisition of the SAES Medical Nitinol business.

Key Takeaways:

  • Kevin Kelly will assume the role of President and CEO at Resonetics on May 30, 2023, succeeding Tom Burns, who will become Executive Chairman of the Board.
  • Kelly is a 25-year veteran in the medical device industry, with extensive global experience and diverse expertise in strategic planning, organizational development, and business transformation.
  • Prior to joining Resonetics, Kelly was President of Becton Dickinson's Surgery business unit, a $1.5 billion global business.
  • Kelly will work with the Resonetics team, as well as equity investors Carlyle and GTCR, to continue building a best-in-class offering for customers and patients worldwide.
  • Kelly holds a bachelor's and master's degree in civil engineering from Tufts University and a master's degree from Harvard Business School.
  • Resonetics is a pioneer in advanced engineering, product development, prototyping, and manufacturing solutions for the MedTech and life sciences industry.
  • The company operates four core business units: Interventional, Advanced Diagnostics, Minimally Invasive Surgery, and Embedded Technologies.
  • Resonetics is ISO 13485:2016 certified and backed by leading private equity firms Carlyle and GTCR.

Statistics:

  • Resonetics has 14 facilities across the United States, Canada, Costa Rica, Israel, and Switzerland.
  • The company employs over 2,000 associates worldwide.
  • The SAES Medical Nitinol business acquisition is pending at the time of Kelly's appointment.
  • Resonetics has a strong financial backing from investors Carlyle and GTCR.

Sources:

  • Resonetics (Original Press Release, Date Not Specified)
  • Resonetics ([Category: Management Changes], Copyright 2017 Contify.com)

Read more